Haodong Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Haodong Xu has a total of 165 co-authors. Here are the top co-authors by number of shared publications:
- Chao Tu
Department of Orthopaedics, The Second Xiangya Hospital of Central South University, Changsha, China
15 shared publications - Zhihong Li
Department of Orthopaedics, The Second Xiangya Hospital of Central South University, Changsha, China
15 shared publications - Xin Jin
Department of Urology The Second Xiangya Hospital Central South University Changsha Hunan China
10 shared publications - Zhongming Zhao
Center for Precision Health, McWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
10 shared publications - Binfeng Liu
Department of Orthopaedics The Second Xiangya Hospital of Central South University Changsha Hunan China
9 shared publications - Chengyao Feng
Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China. 1
9 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
KinaseMD 2.0: an updated database of kinase mutations and drug response
Kinase mutations can alter activity, inhibitor response and downstream phosphorylation signaling, particularly within four resistance-associated substructures: gatekeeper, G-loop, αC-helix, and A-loop. KinaseMD 2.0 (http://modinfor.com/KinaseMD/) updates the kinase-centered database in three areas. Integrating source-curated annotations with Dr. Kinase predictions expanded substructure annotations from 1162 to 13 522 and kinase coverage from 388 to 547. Updated pharmacogenomic and signaling layers contain 422 244 drug-response measurements, 1614 candidate drug-resistance evidence records, and 359 600 predicted phosphorylation-network rewiring events. The new Kinase Perturbation Evidence Mapping (KPEM) workflow combines LLM-based literature extraction from an initial collection of over 480 000 publications with standardized processing of 30 public drug-treatment phosphoproteomic datasets. It provides 23 757 kinase-level records of literature-reported evidence and 53 029 phosphoproteomic records across 5124 drug/agent categories and 1598 disease contexts, distinguishing reported phosphorylation evidence from inferred kinase-associated signaling responses. By linking resistance-associated substructures, cancer mutations, drug response, and phosphorylation signaling, KinaseMD 2.0 supports studies of drug-resistance mechanisms and kinase-inhibitor design and development.
- 12 November 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
Open AccessKinaseMD 2.0: an updated database of kinase mutations and drug response
Kinase mutations can alter activity, inhibitor response and downstream phosphorylation signaling, particularly within four resistance-associated substructures: gatekeeper, G-loop, αC-helix, and A-loop. KinaseMD 2.0 (http://modinfor.com/KinaseMD/) updates the kinase-centered database in three areas. Integrating source-curated annotations with Dr. Kinase predictions expanded substructure annotations from 1162 to 13 522 and kinase coverage from 388 to 547. Updated pharmacogenomic and signaling layers contain 422 244 drug-response measurements, 1614 candidate drug-resistance evidence records, and 359 600 predicted phosphorylation-network rewiring events. The new Kinase Perturbation Evidence Mapping (KPEM) workflow combines LLM-based literature extraction from an initial collection of over 480 000 publications with standardized processing of 30 public drug-treatment phosphoproteomic datasets. It provides 23 757 kinase-level records of literature-reported evidence and 53 029 phosphoproteomic records across 5124 drug/agent categories and 1598 disease contexts, distinguishing reported phosphorylation evidence from inferred kinase-associated signaling responses. By linking resistance-associated substructures, cancer mutations, drug response, and phosphorylation signaling, KinaseMD 2.0 supports studies of drug-resistance mechanisms and kinase-inhibitor design and development.
- 25 October 2026
- Published by Taylor & Francis in Autophagy
- p. 1-3
PRKN dephosphorylation by PTEN-L couples mitophagy inhibition to GSDME pyroptosis suppression
- 25 October 2026
- Published by Taylor & Francis in Autophagy
- p. 1-3
PRKN dephosphorylation by PTEN-L couples mitophagy inhibition to GSDME pyroptosis suppression
- Open Access
NeoOmni Atlas: an integrated database for pan-cancer neoantigen derived from proteogenomics analysis
Tumor neoantigens derived from diverse molecular aberrations are important targets for personalized cancer immunotherapy, but existing resources incompletely integrate mass-spectrometry-supported canonical and non-canonical antigen evidence across cancer types. NeoOmni Atlas is an interactive pan-cancer T-cell epitope resource, built via proteogenomic reanalysis of 7,561 immunopeptidomics datasets comprising 511 million raw spectra from 2,341 samples across 26 cancer types. The analysis yielded 872,414 eluted canonical peptides and 198,961 non-canonical peptides spanning 18 molecular alteration classes, along with 759,386 unique ligands presented by 322 human leukocyte antigen (HLA) alleles. Relative to existing repositories, NeoOmni Atlas covers a broader range of cancer types, includes 60 additional HLA alleles, and catalogs 369,781 novel ligands. A computational tumor-specific filtering framework identified 316,126 tumor-associated epitopes and 61,231 tumor-specific epitopes. Tumor-specific epitopes showed stronger predicted binding affinity than tumor-associated epitopes for HLA class I A and B alleles, and 65 conserved tumor-specific epitopes recurrent across more than 10 tumor types represent potential shared antigen candidates. NeoOmni Atlas also prioritizes candidate tumor-associated antigens including PMEL (gp100:209–217) and CSPG4 , and supports browsing, searching, and downloading by cancer type, human leukocyte antigen allele, peptide sequence, and source event. NeoOmni Atlas is freely accessible at http://modinfor.com/NeoOmni-Atlas/ .
Open AccessNeoOmni Atlas: an integrated database for pan-cancer neoantigen derived from proteogenomics analysis
Tumor neoantigens derived from diverse molecular aberrations are important targets for personalized cancer immunotherapy, but existing resources incompletely integrate mass-spectrometry-supported canonical and non-canonical antigen evidence across cancer types. NeoOmni Atlas is an interactive pan-cancer T-cell epitope resource, built via proteogenomic reanalysis of 7,561 immunopeptidomics datasets comprising 511 million raw spectra from 2,341 samples across 26 cancer types. The analysis yielded 872,414 eluted canonical peptides and 198,961 non-canonical peptides spanning 18 molecular alteration classes, along with 759,386 unique ligands presented by 322 human leukocyte antigen (HLA) alleles. Relative to existing repositories, NeoOmni Atlas covers a broader range of cancer types, includes 60 additional HLA alleles, and catalogs 369,781 novel ligands. A computational tumor-specific filtering framework identified 316,126 tumor-associated epitopes and 61,231 tumor-specific epitopes. Tumor-specific epitopes showed stronger predicted binding affinity than tumor-associated epitopes for HLA class I A and B alleles, and 65 conserved tumor-specific epitopes recurrent across more than 10 tumor types represent potential shared antigen candidates. NeoOmni Atlas also prioritizes candidate tumor-associated antigens including PMEL (gp100:209–217) and CSPG4 , and supports browsing, searching, and downloading by cancer type, human leukocyte antigen allele, peptide sequence, and source event. NeoOmni Atlas is freely accessible at http://modinfor.com/NeoOmni-Atlas/ .
- Open Access
- 28 September 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (21) , 6166-6190
PTEN-L inhibits mitophagy and GSDME-dependent pyroptosis via Parkin dephosphorylation
Mitochondrial dysfunction is a potent trigger of inflammatory cell death; however, the precise signaling pathways linking mitochondrial damage to pyroptosis remain incompletely understood. Here, we identify a previously unrecognized pathway in which mitochondrial depolarization activates the PINK1–Parkin axis to drive GSDME-mediated pyroptosis, a process negatively regulated by the phosphatase PTEN-L. Upon activation, Parkin promotes the ubiquitination and proteasomal degradation of MCL-1, facilitating mitochondrial translocation and activation of BAX. This triggers cytochrome c release, caspase-3 activation, and subsequent cleavage and plasma membrane targeting of GSDME, ultimately leading to pyroptotic cell death. Conversely, PTEN-L functions as a master negative regulator that counteracts Parkin through dephosphorylation and inactivation of Parkin. This action not only suppresses mitophagy but also stabilizes MCL-1, thereby inhibiting the downstream BAX/BAK–caspase-3–GSDME cascade and subsequent pyroptosis. Thus, our findings reveal a phosphorylation-dependent regulatory switch centered on Parkin that functionally couples mitophagy regulation to GSDME-dependent pyroptosis, delineating a novel mitochondrial signaling pathway that integrates organelle quality control with cellular fate decisions under stress conditions.
- 28 September 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (21) , 6166-6190
Open AccessPTEN-L inhibits mitophagy and GSDME-dependent pyroptosis via Parkin dephosphorylation
Mitochondrial dysfunction is a potent trigger of inflammatory cell death; however, the precise signaling pathways linking mitochondrial damage to pyroptosis remain incompletely understood. Here, we identify a previously unrecognized pathway in which mitochondrial depolarization activates the PINK1–Parkin axis to drive GSDME-mediated pyroptosis, a process negatively regulated by the phosphatase PTEN-L. Upon activation, Parkin promotes the ubiquitination and proteasomal degradation of MCL-1, facilitating mitochondrial translocation and activation of BAX. This triggers cytochrome c release, caspase-3 activation, and subsequent cleavage and plasma membrane targeting of GSDME, ultimately leading to pyroptotic cell death. Conversely, PTEN-L functions as a master negative regulator that counteracts Parkin through dephosphorylation and inactivation of Parkin. This action not only suppresses mitophagy but also stabilizes MCL-1, thereby inhibiting the downstream BAX/BAK–caspase-3–GSDME cascade and subsequent pyroptosis. Thus, our findings reveal a phosphorylation-dependent regulatory switch centered on Parkin that functionally couples mitophagy regulation to GSDME-dependent pyroptosis, delineating a novel mitochondrial signaling pathway that integrates organelle quality control with cellular fate decisions under stress conditions.
- 7 September 2026
- Published by Elsevier in Expert Systems with Applications
- Vol. 333
PAS-Mamba: Phase-Amplitude-Spatial state space model for MRI reconstruction
- 7 September 2026
- Published by Elsevier in Expert Systems with Applications
- Vol. 333
PAS-Mamba: Phase-Amplitude-Spatial state space model for MRI reconstruction
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from PRKDC Induces Chemoresistance in Osteosarcoma by Recruiting GDE2 to Stabilize GNAS and Activate AKT
Supplementary Table of the manuscript
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from PRKDC Induces Chemoresistance in Osteosarcoma by Recruiting GDE2 to Stabilize GNAS and Activate AKT
Supplementary Table of the manuscript
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from PRKDC Induces Chemoresistance in Osteosarcoma by Recruiting GDE2 to Stabilize GNAS and Activate AKT
Supplementary Figures of the manuscript
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from PRKDC Induces Chemoresistance in Osteosarcoma by Recruiting GDE2 to Stabilize GNAS and Activate AKT
Supplementary Figures of the manuscript
- 16 April 2026
- Published by Elsevier in Journal of Molecular Biology
- Vol. 438 (18) , 169815
Deeptosis: A Deep Learning-Based Platform for Label-Free Discrimination of Apoptosis and Pyroptosis from Brightfield Microscopy
- 16 April 2026
- Published by Elsevier in Journal of Molecular Biology
- Vol. 438 (18) , 169815
Deeptosis: A Deep Learning-Based Platform for Label-Free Discrimination of Apoptosis and Pyroptosis from Brightfield Microscopy
- Open Access
- 28 November 2025
- Published by Springer Nature in Nature Methods
- Vol. 23 (1) , 1-12
Assessment of computational methods in predicting TCR–epitope binding recognition
T cell receptors (TCRs) play a vital role in immune recognition by binding specific epitopes. Accurate prediction of TCR–epitope interactions is fundamental for advancing immunology research. Although numerous computational methods have been developed, a comprehensive evaluation of their performance remains lacking. Here we assessed 50 state-of-the-art TCR–epitope prediction models using 21 datasets covering 762 epitopes and hundreds of thousands binding TCRs. Our analysis revealed that the source of negative TCRs substantially impacts model accuracy, with external negatives potentially introducing uncontrolled confounders. Model performance generally improved with more TCRs per epitope, highlighting the importance of large and diverse datasets. Models incorporating multiple features typically outperformed those using only complementarity-determining region 3β information, yet all struggle to generalize to unseen epitopes. The use of independent test sets proved crucial for unbiased assessment on both seen and unseen epitopes. These insights will guide the development of more accurate and generalizable TCR–epitope prediction models for real-world applications.
- 28 November 2025
- Published by Springer Nature in Nature Methods
- Vol. 23 (1) , 1-12
Open AccessAssessment of computational methods in predicting TCR–epitope binding recognition
T cell receptors (TCRs) play a vital role in immune recognition by binding specific epitopes. Accurate prediction of TCR–epitope interactions is fundamental for advancing immunology research. Although numerous computational methods have been developed, a comprehensive evaluation of their performance remains lacking. Here we assessed 50 state-of-the-art TCR–epitope prediction models using 21 datasets covering 762 epitopes and hundreds of thousands binding TCRs. Our analysis revealed that the source of negative TCRs substantially impacts model accuracy, with external negatives potentially introducing uncontrolled confounders. Model performance generally improved with more TCRs per epitope, highlighting the importance of large and diverse datasets. Models incorporating multiple features typically outperformed those using only complementarity-determining region 3β information, yet all struggle to generalize to unseen epitopes. The use of independent test sets proved crucial for unbiased assessment on both seen and unseen epitopes. These insights will guide the development of more accurate and generalizable TCR–epitope prediction models for real-world applications.